Dermavant Reports P-III Trial (ADORING 2) Results of Vtama (tapinarof) for Atopic Dermatitis

Share this

Dermavant Reports P-III Trial (ADORING 2) Results of Vtama (tapinarof) for Atopic Dermatitis


  • The P-III trial (ADORING 2) evaluating topical Vtama (1%) vs vehicle in a ratio (2:1) in pediatrics aged ≤2yrs. and adult patients with AD
  • The results showed that 46.4% vs 18.0% of patients treated with Vtama cream achieved the 1EPs of a vIGA-AD of clear (0) or almost clear (1) with a 2-grade improvement from baseline @8wk., 59.1% vs 21.2 % achieved the 2EPs of the proportion of patients with ≥75% improvement in EASI, 52.8% vs 24.1% of patients aged ≥12yrs. with a baseline PP-NRS score ≥4 achieved a ≥4-point reduction in the PP-NRS @8wk.
  • AEs were mild to mod. with a low study discontinuation rate due to AEs (1.5% vs 3.0%) & no safety or tolerability signals were reported. Vtama, a novel aryl hydrocarbon receptor agonist cream & was approved in the US for the topical treatment of PsO in adults

Ref: Dermavant | Image: Dermavant

Related News:- Dermavant’s Vtama (tapinarof) Receives the US FDA’s Approval for the Treatment of Plaque Psoriasis in Adults

Click here to­ read the full press release 

Senior Editor

Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions